Eledon Pharmaceuticals Inc Stock
Eledon Pharmaceuticals Inc Stock price
Key metrics
| Market capitalization | $259.87m |
| Enterprise Value | $182.18m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 2.36 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-56.22m |
| Free Cash Flow (TTM) Free Cash Flow | $-37.42m |
| Cash position | $78.19m |
Is Eledon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Eledon Pharmaceuticals Inc Stock Analysis
Analyst Opinions
5 Analysts have issued a Eledon Pharmaceuticals Inc forecast:
Analyst Opinions
5 Analysts have issued a Eledon Pharmaceuticals Inc forecast:
Financial data from Eledon Pharmaceuticals Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.37 -0.37 |
0%
0%
|
|
| EBITDA | -56 -56 |
32%
32%
|
EBIT (Operating Income) EBIT | -56 -56 |
32%
32%
|
| Net Profit | -100 -100 |
12%
12%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Eledon Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eledon Pharmaceuticals Inc Stock News
Company Profile
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
| Head office | United States |
| CEO | David-Alexandre Gros |
| Employees | 20 |
| Founded | 2004 |
| Website | eledon.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
